NorthRock Partners LLC Has $1.49 Million Position in Edwards Lifesciences Co. (NYSE:EW)

NorthRock Partners LLC grew its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 102.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 20,097 shares of the medical research company's stock after purchasing an additional 10,183 shares during the quarter. NorthRock Partners LLC's holdings in Edwards Lifesciences were worth $1,488,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in EW. Crowley Wealth Management Inc. purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at $26,000. Millstone Evans Group LLC purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Edwards Lifesciences during the fourth quarter worth about $30,000. Roble Belko & Company Inc purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $46,000. Finally, Catalyst Capital Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $54,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Trading Up 0.0%

Edwards Lifesciences stock traded up $0.02 during mid-day trading on Tuesday, hitting $78.06. The stock had a trading volume of 1,985,324 shares, compared to its average volume of 5,091,403. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The stock has a 50-day simple moving average of $72.27 and a two-hundred day simple moving average of $71.86. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $45.79 billion, a PE ratio of 11.21, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter last year, the business posted $0.66 EPS. The firm's revenue was up 6.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling

In other news, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $74.40, for a total value of $837,000.00. Following the completion of the transaction, the chief financial officer now directly owns 41,098 shares in the company, valued at approximately $3,057,691.20. The trade was a 21.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 400 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the sale, the vice president now directly owns 22,588 shares in the company, valued at approximately $1,569,414.24. This represents a 1.74% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 66,192 shares of company stock worth $4,709,454 over the last ninety days. Company insiders own 1.29% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on EW. StockNews.com downgraded Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday. Truist Financial reduced their target price on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Piper Sandler lifted their price objective on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research note on Tuesday, May 13th. Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Finally, Barclays boosted their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of "Hold" and an average target price of $79.60.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.